A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness

General Information

Summary The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and Hypoglycemia Unawareness and maintained safely for up to two years. It will also test if VC-02 is an effective treatment for these subjects.
Clinical trials phase Phases 1/2
Start date (estimated) 2017-07-06
End date (estimated) 2020-12-31
Clinical feature
Label Diabetes Mellitus, Type 1
Link http://purl.obolibrary.org/obo/OMIT_0005198

Administrative Information

NCT number NCT03163511
ICTRP weblink http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT03163511
Other study identifiers
Name VC02-101
Source weblink http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT03163511
Regulatory body approval
Public contact
Email info@viacyte.com
Sponsors ViaCyte

Cell Line

Stem cell lines obtained from


Recruitment Status Recruiting
Estimated number of participants 55